Respiratory Disorders Treatment Market Size, Share, and Trends 2024 to 2034

Respiratory Disorders Treatment Market Size to Hit USD 206.19 Bn by 2034 

The global respiratory disorders treatment market size was USD 107.50 billion in 2023, calculated at USD 114.05 billion in 2024 and is expected to reach around USD 206.19 billion by 2034, expanding at a CAGR of 6.10% from 2024 to 2034. The rising emphasis on personalized medicine is observed to support the overall expansion of the market.

Respiratory Disorders Treatment Market Key Takeaways

• North America held the dominant share of the respiratory disorders treatment market in 2023. The region is observed to witness notable growth during the forecast period.
• Asia Pacific is observed to expand rapidly during the forecast period.
• By disease, the asthma segment accounted for the dominating share of the market in 2023.
• By disease, the Chronic Obstructive Pulmonary Disease (COPD) segment is observed to grow at a notable rate during the forecast period.
• By drug class, the combination drugs segment held the largest share of the respiratory disorders treatment market in 2023.
• By drug class, the bronchodilators segment is expected to grow significantly during the forecast period.
• By route of administration, the nasal segment led the market in 2023.
• By route of administration, the oral segment is expected to grow at a notable rate.
• By distribution channel, the retail pharmacies segment held the largest share of the market in 2023.
• By distribution channel, the online pharmacies segment is expected to grow fastest during the forecast period in the respiratory disorders treatment market.

Market Overview

Respiratory disorder is a medical condition that affects a person's respiratory system. COPD and asthma are the most common and chronic types of respiratory diseases. Respiratory disorders affect the lungs and airways of a person. The respiratory disorders treatment market offers treatment and solutions vary from patient to patient. It is generally based on the diagnostic results. Common respiratory disorder treatments include medications, oxygen therapy, allergen immunotherapy, pulmonary rehabilitation, and others. Doctors often prescribe medications that include corticosteroids, bronchodilators, antibiotics (for bacterial infections), antiviral drugs), and several other medications to treat symptoms and underlying causes. Some of the causes of respiratory disorders include smoking, air pollution, allergic reactions to certain substances, exposure to harmful chemicals, respiratory infections, and genetics.

Respiratory Disorders Treatment Market Growth Factors

• The rising adoption of digital health technologies such as wearable devices, mobile apps, and telemedicine platforms assists patients with respiratory disorders in regularly monitoring symptoms, tracking lung function, and accessing advanced healthcare services. It is expected to accelerate the growth of the global respiratory disorders treatment market during the forecast period.
• The increasing demand for precision medicine along with personalized care is projected to offer significant opportunities for the market’s expansion.
• The supportive government program and initiatives regarding the preventive measures and treatment of early respiratory disorder symptoms are expected to support the market’s expansion during the forecast period.
• The escalation in demand for digital inhalers for asthma is expected to fuel the growth of the respiratory disorders treatment market.
• The rapid innovation of innovative medications for the effective treatment of respiratory disorders is expected to propel the market’s growth in the coming years.

Market Scope

Market Dynamics

Drivers

Increasing prevalence of respiratory diseases

The prevalence of respiratory diseases across the globe is anticipated to boost the growth of the global respiratory disorders treatment market during the forecast period. The market has witnessed increasing cases of respiratory diseases such as asthma, respiratory infections chronic obstructive pulmonary disorders (COPD), and bronchiectasis, spurring the demand for respiratory disorder treatments globally. COPD is mostly treated through inhaled corticosteroids. Chronic respiratory disorders can also be treated with bronchodilators and antibiotics.

Respiratory diseases encompass serious health conditions that affect the tissues involved in breathing which include lungs and airways. These respiratory disorders can have several causes such as environmental, smoking tobacco, air pollution, exposure to certain harmful substances, genetic predispositions, and others. Comprehending the underlying causes is important for early diagnosis, prevention, and effective treatment. Therefore, the rising burden of respiratory disorders supports the expansion of innovative treatment of respiratory disorders treatment options globally in the coming years.

• According to the Global Initiative for Asthma (GINA), Asthma is one of the most common chronic non-communicable diseases that affects over 260 million people and is responsible for over 450000 deaths each year worldwide.
• According to the WHO, COPD is the seventh leading cause of poor health globally. Tobacco smoking accounts for over 70% of COPD cases in high-income countries. In LMIC tobacco smoking accounts for 30–40% of COPD cases, and household air pollution is a major risk factor.

Restraint

Lack of healthcare facilities

The lack of advanced healthcare facilities in certain areas is anticipated to hamper the growth of the respiratory disorders treatment market. Accessing better healthcare facilities can be challenging for people residing in rural areas and middle and lower-income countries. Moreover, the high cost of medications can also pose a challenge for poor people to get the proper care they need and afford their medications. Several middle and lower-income countries also lack advanced diagnostic infrastructure, which is likely to restrict the expansion of the respiratory disorders treatment market.

Opportunity

The rising popularity of biologic therapies

The rising popularity of biologic therapies is projected to offer a significant opportunity for the growth of the global respiratory disorders treatment market in the coming years. Biologic therapies for highly effective for severe asthma. It is a type of treatment that targets specific molecules and pathways involved in the inflammation and immune response associated with asthma. Biologic therapies have revolutionized the treatment of asthma by reducing the frequency and severity of asthma attacks in patients with uncontrolled asthma.

Biologic infusion therapies are effective in targeting specific antibodies, molecules, and cells involved in the inflammatory response associated with asthma and other respiratory diseases. Biologics including mepolizumab, omalizumab, dupilumab, and benralizumab are highly preferred as personalized treatment options for patients with severe asthma or eosinophilic COPD. Therefore, the adoption of such therapies reduces exacerbations of respiratory disorders, improves lung function, and enhances the quality of life.

Disease Insights

The asthma segment accounted for the dominating share of the respiratory disorders treatment market in 2023 and is also projected to continue its dominance over the forecast period owing to the rising cases of asthma globally. Asthma is one of the noncommunicable diseases (NCD), affecting both children and adults. Asthma is the most common chronic disease among children. Asthma is caused by the inflammation and narrowing of the airways in the lungs which significantly impact a person's breathing, chest tightness, and a combination of coughing as well as wheezing. Pharmaceutical companies are actively involved in the development of long-acting bronchodilators, triple therapy regimens, combination inhalers, and fixed-dose combinations for treating patients with asthma. Thereby driving the growth of the segment.

The Chronic Obstructive Pulmonary Disease (COPD) segment is observed to witness a notable rate of growth in the global respiratory disorders treatment market over the forecast period. The segment growth is driven by the rising burden of COPD cases around the world. COPD is a serious lung disease causing restricted airflow and breathing problems. The lungs can get damaged or clogged with phlegm. Smoking and air pollution are usually the most common causes of COPD.  According to the American Lung Association, in 2022, 11.7 million people, or 4.6% of adults, reported a diagnosis of COPD.

The National Institutes of Health (NIH) reports that models project a 23% increase in COPD cases worldwide among adults 25 years of age and older between 2020 and 2050, bringing the total number of COPD patients to approximately 600 million by that time. The COPD burden was expected to increase more among women and in low- and middle-income areas. By 2050, it was predicted that the number of cases in low- and middle-income countries would more than double that of high-income regions, with the number of cases for females estimated to climb by 47.1% compared to a 9.4% increase for males.

Drug Class Insights

The combination drugs segment held the largest share of the respiratory disorders treatment market in 2023, the segment is expected to sustain the position throughout the forecast period. The combination drugs segment is driven by the rising innovation in long-term therapy including combination therapy to alleviate the symptoms of respiratory disorders and improve patient’s well-being. Thereby, bolstering the segment’s growth. In November 2023, Pharma major Lupin Limited announced the launch of the world’s first fixed-dose triple combination drug (FDC) under the Vilfuro-G brand for the treatment of chronic obstructive pulmonary disease (COPD) in India.

The bronchodilators segment is expected to grow significantly during the forecast period owing to the increasing prevalence of asthma and COPD globally. Bronchodilators are gaining immense popularity in treating respiratory diseases including asthma, COPD, and chronic bronchitis. Bronchodilator medication relaxes the muscles surrounding the airways which makes breathing easier.

• In June 2024 Verona Pharma plc announced the US Food and Drug Administration approved Ohtuvayre (ensifentrine) for the maintenance treatment of chronic obstructive pulmonary disease (COPD) in adult patients. Ohtuvayre is the first inhaled product with a novel mechanism of action available for the maintenance treatment of COPD in more than 20 years.

Route of Administration Insights

The nasal segment held the largest share of the respiratory disorders treatment market. The nasal segment is anticipated to be highly lucrative for respiratory disorders treatment during the forecast period owing to the rising demand for nasal drug therapy for treating respiratory disorders. Medications administered nasally are quickly absorbed through the nasal mucosa, providing faster relief from symptoms compared to some other delivery methods. This is particularly beneficial for acute respiratory conditions like asthma attacks or severe allergies. Nasal treatments deliver medication directly to the respiratory tract, targeting the affected areas more effectively. This localized approach can enhance the efficacy of the treatment and reduce systemic side effects.

The oral segment is expected to grow at a notable rate in the respiratory disorders treatment market. Oral treatments are often associated with higher patient compliance. Patients are more likely to adhere to a treatment regimen that involves taking pills or tablets as opposed to using inhalers or receiving injections. Many oral medications for respiratory disorders, such as bronchodilators and corticosteroids, are widely available and can be easily prescribed by doctors, making them a common choice for initial and ongoing treatment.

Distribution Channel Insights

The retail pharmacies segment held the largest share of the respiratory disorders treatment market in 2023 owing to the surge in the number of respiratory therapeutics being dispensed through retail pharmacies. Additionally, rising accessibility to skilled medical staff and healthcare professionals helps to establish better interaction with the patient as well as easy availability of all kinds of specialized drugs makes these pharmacies a major channel of distribution, driving the growth of the segment.

On the other hand, the online pharmacies segment is expected to grow fastest during the forecast period. Online pharmacies are offering attractive discounts and ensuring the availability of a wide variety of drugs. Moreover, attractive discounts attract patients to online pharmacies, contributing to the growth of online pharmacies as a significant distribution channel. Therefore, the rapid growth of the e-commerce sector is projected to boost the segment expansion during the forecast period.

Regional Insights

North America held the dominant share of the respiratory disorders treatment market in 2023. The region is home to well-established healthcare facilities, doctors, and medical professionals who specialize in treating respiratory disorders. The region is observed to witness notable growth during the forecast period owing to the presence of well-established healthcare infrastructure, increasing healthcare expenses, rising development of innovative medications, and rising cases of respiratory disorders like asthma and COPD. With the presence of key market players and the expansion of strategic agreements among key players is expected to continue to boost the market’s growth in the coming years.

Additionally, the rising adoption of combination drugs, increasing accessibility of target therapies, and introduction of new drugs are anticipated to drive the expansion of the market in the region. Thus, such factors are expected to drive the market growth in the region during the forecast period.

• According to the Asthma and Allergy Foundation of America report published in April 2024, nearly, 27 million people in the U.S. have asthma. This equals about 1 in 12 people. Over 22 million U.S. adults ages 18 and older have asthma. It is a leading chronic disease in children. There are nearly 4.5 million children under the age of 18 with asthma.
• According to the CDC, the number of visits to emergency departments with COPD as the primary diagnosis is nearly 791,000.

Asia Pacific is observed to expand rapidly during the forecast period. The regional growth of the respiratory disorders treatment market during the forecast period is driven by the increasing investment in the healthcare infrastructure to improve healthcare facilities and expand access to respiratory services. In addition, the rise in the aging population, increasing consumption of tobacco smoking, and air pollution have led to an increasing prevalence of COPD and asthma which further increases the demand for medications, inhalers, and breathing tests in the region.

Pharmaceutical companies are highly investing in research and development to launch pharmacological agents, inhalation devices, and drug delivery technologies for better respiratory disorder treatment in the region. Furthermore, advancement in diagnostic facilities, increasing awareness of early diagnosis, and increasing introduction of respiratory devices is expected to drive the growth of the market in the region during the forecast period.

India has a high burden of asthma, according to the Global Asthma Report 2022, prepared by Global Asthma Network (GAN) has published that nearly 35 million people suffer from asthma in India. the study has also shown that 82% of patients with early symptoms and 70% of patients with severe asthma remain undiagnosed in India.

Respiratory Disorders Treatment Market Companies

• AstraZeneca plc
• Boehringer Ingelheim International GmbH
• F. Hoffmann-La Roche Ltd.
• GlaxoSmithKline plc
• Merck & Co., Inc.
• Mylan N.V
• Novartis AG
• Sanofi
• Sunovion Pharmaceuticals, Inc.
• Cipla
• Vertex Pharmaceuticals Incorporated.
• Teva Pharmaceutical Industries
• CHIESI Farmaceutici S.p.A.

Recent Developments

• In March 2024, to address this growing concern, AIIMS Raipur organized a symposium aimed at discussing new medical methodologies for ILD treatment. Medical experts highlighted the alarming surge in ILD cases due to factors such as smoking and air pollution.
• In March 2023, Affibody AB and Chiesi Farmaceutici S.p.A have announced a collaboration and licensing agreement to develop and commercialize innovative treatments for respiratory diseases using Affibody’s proprietary technology. Under the terms of the agreement, the parties will collaborate to progress up to three programs based on Affibody molecules against undisclosed targets for respiratory diseases.
• In September 2023, AlveoGene launched with first inhaled delivery treatment for rare respiratory disorders. A new UK-based gene therapy company has entered the sector starting with the launch of an inhaled delivery treatment for rare respiratory disorders.

Segments Covered in the Report

By Disease

• Asthma
• Chronic Obstructive Pulmonary Disease (COPD)
• Lung Cancer
• Respiratory Tract Infection
• Allergic Rhinitis
• Cystic Fibrosis (CF)
• Others

By Drug Class

• Bronchodilators
• Corticosteroids
• Combination Drugs
• Antibiotics
• Target Therapy
• Immunotherapy
• CFTR
• Others

By Route of Administration

• Oral
• Nasal
• Injectable

By Distribution Channel

• Retail Pharmacies
• Hospital Pharmacies
• Online Pharmacies

By Geography

• North America
• Asia Pacific
• Europe
• Latin America
• Middle East & Africa